InvestorWire NewsRoom


Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit
July 2, 2021

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit

  • Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development
  • The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT
  • It will focus on the psychedelics industry, showcasing the latest research and development within the sector
  • Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, will share information on the company, along with its drug development pipeline

In an official statement dated June 24, 2021, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) confirmed that it would participate in the Psych Investor Summit: Research and Development.

The virtual event, scheduled on Wednesday, July 7, 2021, from 11:50 a.m. to 12:50 p.m. EDT, will focus on the psychedelics industry, mainly showcasing the latest research and development within the sector ( The event is also intended to expand businesses currently looking for capital, mainly by directly delivering the industry’s most promising opportunities to funds and investors.

The July 7 event marks the second global psychedelics industry investment event that solely focuses on research and development. As has been the case with the previous events, this one is meant to showcase the latest clinical evidence for this promising sector. It will feature a concise half-day program, with provisions for interactions with industry leaders, global psychedelics investors and rising entrepreneurs ( 

Tryp Therapeutics is a pharmaceutical enterprise committed to developing bioscience solutions for conditions with unmet needs ( Its current flagship program involves developing a synthetic psychedelic drug candidate specifically designed to treat particular pain and eating disorder indications. Its trademarked Psilocybin-for-Neuropsychiatric Disorder (“PFN”) program is the basis for the company’s development of treatments for several diseases that lack effective treatment options ( 

At this Psych Investor Summit, Tryp Therapeutics, through its Chairman and Chief Executive Officer, Mr. Greg McKee, will share the strides that it has made so far. More specifically, Mr. McKee will delve into more detail on Tryp’s drug development pipeline and what it is doing to push the envelope regarding the use of psychedelics to treat specific types of pain and diseases ( 

Mr. McKee will also contribute to a panel discussion on the future of research and development and the development activities for psychedelic drug compounds. Other speakers presenting at the conference include Rick Doblin, the Founder and Executive Director of MAPS; Christian Angermayer, the Founder of atai Life Sciences; and Dr. Ben Sessa, the Chief Medical Officer at Awkn Life Sciences.

For more information, visit the company’s website at Should you wish to attend the summit, you can register at www.Psych.Global/agenda/.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).